N@N

Radient Pharmaceuticals Files Extension for Third Quarter 2009 Financial Results

_{//health-fitness.news-articles.net/content/2009/ .. on-for-third-quarter-2009-financial-results.html}
^{Published in Health and Fitness on Monday, November 16th 2009 at 17:48 GMT by Market Wire}  

TUSTIN, CA--(Marketwire - November 16, 2009) - Radient Pharmaceuticals Corporation (NYSE Amex: [ RPC ]), a US-based pharmaceutical company, announced today it has filed a Notification of Late Filing under Rule 12b-25 of the Securities Exchange Act of 1934, as amended, with the Securities and Exchange Commission (the "SEC") for its Quarterly Report on Form 10-Q for the third quarter ended September 30, 2009.

This filing provides for an extension for the filing of its Quarterly Report on Form 10-Q until November 23, 2009. The Company's Quarterly Report on Form 10-Q for the nine months ended September 30, 2009, could not be filed within the prescribed period because the Company was unable to compile certain information required in order to permit the Company to file a timely and accurate report on the Company's financial condition. This inability could not have been eliminated by the Company without unreasonable effort or expense. We expect to file the Quarterly Report within the allotted time. For additional information contact Radient Pharmaceutical Corporation's Investor Relations at 206.310.5323.

About Radient Pharma:

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

Forward Looking Statements:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.